464 related articles for article (PubMed ID: 23728312)
1. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
Nelson RL; Suda KJ; Evans CT
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
[TBL] [Abstract][Full Text] [Related]
4. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R
Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile infection in older adults: a review and update on its management.
Kee VR
Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
[TBL] [Abstract][Full Text] [Related]
8. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
10. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
11. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.
Nelson R
Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Mullane KM; Miller MA; Weiss K; Lentnek A; Golan Y; Sears PS; Shue YK; Louie TJ; Gorbach SL
Clin Infect Dis; 2011 Sep; 53(5):440-7. PubMed ID: 21844027
[TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin--the new drug for Clostridium difficile infection.
Vaishnavi C
Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
[TBL] [Abstract][Full Text] [Related]
15. Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis.
Dai J; Gong J; Guo R
Eur J Clin Pharmacol; 2022 Nov; 78(11):1727-1737. PubMed ID: 36057672
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
[TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
Poxton IR
Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea.
Clutter DS; Dubrovskaya Y; Merl MY; Teperman L; Press R; Safdar A
Antimicrob Agents Chemother; 2013 Sep; 57(9):4501-5. PubMed ID: 23836168
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
[TBL] [Abstract][Full Text] [Related]
20. Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
Johnson S; Gerding DN; Louie TJ; Ruiz NM; Gorbach SL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4043-5. PubMed ID: 22615287
[No Abstract] [Full Text] [Related]
[Next] [New Search]